Artemether Plus Benflumetol - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Artemether Plus Benflumetol

The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

Royce C – 1st expert on this subject based on the ideXlab platform

  • Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.
    Southeast Asian Journal of Tropical Medicine and Public Health, 1997
    Co-Authors: Jiao X, Liu Gy, Shan Co, Zhao X, Li Xw, Gathmann I, Royce C

    Abstract:

    The efficacy of a new combination antimalarial therapy CGP 56697 (Artemether Plus Benflumetol) was evaluated in 102 Chinese adults from Hainan Province with untreated falciparum malaria. Each patient received oral doses of 80 mg of Artemether and 480 mg of Benflumetol at 0 8 24 and 48 hours. To prevent reinfection study participants were kept for 28 days in a transmission-free hospital in an area with chloroquine-resistant falciparum malaria. At 28 days 98 (96.1%) of the 102 patients were free of infection. Parasite reduction at 24 hours was 99.4%. The median time required to effect complete fever clearance was 8 hours (range 6-78 hours). The recrudescence rate was only 3.9% and all 4 of these patients responded to artesunate rescue therapy. There were no serious side effects. These findings confirm the rapid onset of CGP 56697 schizonticidal activity and the efficacy of this combination therapy. Additional comparative trials of CGP 56697 are underway in malaria-endemic areas in Africa India and Thailand.

Jiao X – 2nd expert on this subject based on the ideXlab platform

  • Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.
    Southeast Asian Journal of Tropical Medicine and Public Health, 1997
    Co-Authors: Jiao X, Liu Gy, Shan Co, Zhao X, Li Xw, Gathmann I, Royce C

    Abstract:

    The efficacy of a new combination antimalarial therapy CGP 56697 (Artemether Plus Benflumetol) was evaluated in 102 Chinese adults from Hainan Province with untreated falciparum malaria. Each patient received oral doses of 80 mg of Artemether and 480 mg of Benflumetol at 0 8 24 and 48 hours. To prevent reinfection study participants were kept for 28 days in a transmission-free hospital in an area with chloroquine-resistant falciparum malaria. At 28 days 98 (96.1%) of the 102 patients were free of infection. Parasite reduction at 24 hours was 99.4%. The median time required to effect complete fever clearance was 8 hours (range 6-78 hours). The recrudescence rate was only 3.9% and all 4 of these patients responded to artesunate rescue therapy. There were no serious side effects. These findings confirm the rapid onset of CGP 56697 schizonticidal activity and the efficacy of this combination therapy. Additional comparative trials of CGP 56697 are underway in malaria-endemic areas in Africa India and Thailand.

Gathmann I – 3rd expert on this subject based on the ideXlab platform

  • Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.
    Southeast Asian Journal of Tropical Medicine and Public Health, 1997
    Co-Authors: Jiao X, Liu Gy, Shan Co, Zhao X, Li Xw, Gathmann I, Royce C

    Abstract:

    The efficacy of a new combination antimalarial therapy CGP 56697 (Artemether Plus Benflumetol) was evaluated in 102 Chinese adults from Hainan Province with untreated falciparum malaria. Each patient received oral doses of 80 mg of Artemether and 480 mg of Benflumetol at 0 8 24 and 48 hours. To prevent reinfection study participants were kept for 28 days in a transmission-free hospital in an area with chloroquine-resistant falciparum malaria. At 28 days 98 (96.1%) of the 102 patients were free of infection. Parasite reduction at 24 hours was 99.4%. The median time required to effect complete fever clearance was 8 hours (range 6-78 hours). The recrudescence rate was only 3.9% and all 4 of these patients responded to artesunate rescue therapy. There were no serious side effects. These findings confirm the rapid onset of CGP 56697 schizonticidal activity and the efficacy of this combination therapy. Additional comparative trials of CGP 56697 are underway in malaria-endemic areas in Africa India and Thailand.